Teligent, Inc. (TLGT): Price and Financial Metrics

Teligent, Inc. (TLGT)

Today's Latest Price: $0.53 USD

0.01 (-1.70%)

Updated Nov 27 1:00pm

Add TLGT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

TLGT Stock Summary

  • With a price/sales ratio of 0.05, Teligent Inc has a higher such ratio than merely 1.17% of stocks in our set.
  • In terms of volatility of its share price, TLGT is more volatile than 98.32% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TLGT comes in at -413.98% -- higher than that of only 1.05% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Teligent Inc, a group of peers worth examining would be ENDP, SSRM, TWER, HL, and CIG.
  • Visit TLGT's SEC page to see the company's official filings. To visit the company's web site, go to

TLGT Stock Price Chart Interactive Chart >

Price chart for TLGT

TLGT Price/Volume Stats

Current price $0.53 52-week high $6.90
Prev. close $0.53 52-week low $0.46
Day low $0.52 Volume 1,281,700
Day high $0.56 Avg. volume 708,117
50-day MA $0.66 Dividend yield N/A
200-day MA $2.39 Market Cap 2.83M

Teligent, Inc. (TLGT) Company Bio

Teligent Inc. is a specialty generic pharmaceutical company developing, manufacturing, and marketing topical formulations in the United States. The company was founded in 1977 and is based in Buena, New Jersey.

TLGT Latest News Stream

Event/Time News Detail
Loading, please wait...

TLGT Latest Social Stream

Loading social stream, please wait...

View Full TLGT Social Stream

Latest TLGT News From Around the Web

Below are the latest news stories about Teligent Inc that investors may wish to consider to help them evaluate TLGT as an investment opportunity.

TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $TLGT #TLGT--TLGT LONG TERM SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Teligent, Inc.

Business Wire | October 2, 2020

The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) 10X Genomics Inc (NASDAQ: TXG ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Beigene Ltd (NASDAQ: BGNE ) Cardiff Oncology Inc (NASDAQ: CRDF ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Evogene Ltd (NASDAQ: EVGN ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) InVitae Corp (NYSE: NVTA ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Kura Oncology Inc (NASDAQ: KURA ) Lantern Pharma Inc. (NASDAQ: LTRN ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Prelude Therapeutics Incorporated (NASDAQ: PRLD ) (listed Thursday) Seattle Genetics, Inc. (NASDAQ: SGEN ) Shockwave Medical Inc...

Benzinga | September 29, 2020

The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDA...

Benzinga | September 4, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Teligent, Inc. (TLGT) CEO Tim Sawyer on Q2 2020 Results - Earnings Call Transcript

Teligent, Inc. (TLGT) Q2 2020 Earnings Conference Call August 19, 2020 08:00 AM ET Company Participants Tim Sawyer - President & Chief Executive Officer Damian Finio - Chief Financial Officer Conference Call Participants Presentation Operator Ladies and gentlemen, thank you for standing by, and welcome to the Teligent, Inc. Second...

SA Transcripts on Seeking Alpha | August 19, 2020

Read More 'TLGT' Stories Here

TLGT Price Returns

1-mo -0.75%
3-mo -55.83%
6-mo -83.28%
1-year -91.24%
3-year -98.68%
5-year -99.39%
YTD -87.56%
2019 -68.91%
2018 -62.26%
2017 -45.08%
2016 -25.73%
2015 1.14%

Continue Researching TLGT

Want to see what other sources are saying about Teligent Inc's financials and stock price? Try the links below:

Teligent Inc (TLGT) Stock Price | Nasdaq
Teligent Inc (TLGT) Stock Quote, History and News - Yahoo Finance
Teligent Inc (TLGT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7338 seconds.